|
Copiague,
January 22, 2002
American Biogenetic Sciences Secures
Vaccine Agreements With Russian Federation Entities
Copiague,
January 9, 2002
American Biogenetic Sciences Updates
Information and Proceeds with Vaccine Aggreements
Copiague,
January 9, 2002
American Biogenetic Sciences Voluntarily
Delists From NASDAQ and Intends to Apply to the OTC
Bulletin Board
Copiague,
November 28, 2001
American Biogenetic Sciences, Inc.
Responds to Inquiries
Mowsow,
Russia, New York, USA, November 26, 2001
ABS
Negotiates Landmark Anthrax and Smallpox vaccine Agreement
Copiague,
November 9, 2001
Abbott Discontinues Liscensing Agreement
Copiague,
September 25, 2001
ABS Awarded Patent for Treating and
Preventing Migraine
Copiague,
August 29, 2001
Biotechnology Value Fund Expands Investment
in American Biogenetic Sciences, Inc.
Copiague,
July 19, 2001
American Biogenetic Sciences TpP™
Test Studies Reported At Paris Conference
Copiague,
July 13, 2001
American Biogenetic Sciences Inc. Receives
NASDAQ Staff Determination Letter
Copiague,
July 2, 2001
American Biogenetic Sciences Inc. Sells
Assets of its Subsidiary, Stellar Bio Systems, Inc.
Copiague,
May 24, 2001
American Biogenetic Sciences Issues
2000 Annual Report
Copiague,
May 21, 2001
Recent Clinical Studies Further Validates
American Biogenetic Sciences TpP™ Test
Copiague,
April 23, 2001
American Biogenetic Sciences, Inc.
Panel Reviews Antibody Technology at International
Meeting of Immunologists
Copiague,
April 3, 2001
Biosite® Diagnostics and American
Biogenetic Sciences sign a Research and License Agreement
for TpP
Copiague,
February 13, 2001
American Biogenetic Sciences, Inc. Obtains U.S. Patent
for the Treatment of Malignant and Benign Tumors
Copiague,
February 5, 2001
American Biogenetic Sciences, Inc. New President Highlights
Progress in 2000 and Business Outlook for 2001
Copiague,
January 11, 2001
American
Biogenetic Sciences, Inc. Announces Management Team
Transition and New Appointments to the Board
Newsday
Article - November 6, 2000
An Entrepreneur for the Ages At 85, Alfred Roach is
still trying to innovate technology
Copiague,-
October 3, 2000
Framingham Heart Study Shows ABS Diagnostic FiF Test
Results Demonstrate a Stronger Association with Cardiovascular
Disease Risk than Traditional Test Methods
Copiague,-
September 27, 2000
American Biogenetic Sciences Named Fastest Growing
Company in the 2000 Long Island Technology Fast 50
Copiague,-
July 19, 2000
American Biogenetic Sciences, Inc. Announces Recent
Publication Affirms TpP Superiority in Evaluating
Deep Vein Thrombosis and Pulmonary Embolism
Copiague,-
July 13, 2000
American Biogenetic Sciences, Inc. Expands Its Therapeutic
Product Pipeline
Copiague,-
July 11, 2000
American Biogenetic Sciences, Inc. Reinstated to NASDAQ
SmallCap Market
Copiague,-
June 28, 2000
American Biogenetic Sciences, Inc. Obtains U.S. Patent
for Unique Radionuclide-Labeling Method for MH-1 and
Other Monoclonal Antibodies
Copiague,-
June 5, 2000
American Biogenetic Sciences, Inc. Announces a Program
to Accelerate Development of ABS-205 for Treatment
of Alzheimer's Disease
Copiague,-
May 4, 2000
American Biogenetic Sciences and Trevigen Have Generated
a New Way to Measure DNA Damage
Copiague,-
March 22, 2000
American Biogenetic Sciences, Inc. to Humanize Its
Unique Monoclonal Antibody
Copiague,-
March 7, 2000
American Biogenetic Sciences, Inc. to Provide Unique
Monoclonal Antibodies to the Pharmaceutical and Biotechnology
Industry
Copiague,-
March 2, 2000
American Biogenetic Sciences's Neuroscience Compound
Will Be Studied in Alzheimer's Model
Copiague,-
February 17, 2000
NASDAQ Agrees to Review Listing Status for American
Biogenetics Sciences, Inc.
Copiague,-
February 10, 2000
American Biogenetic Sciences, Inc. Receives $3.0 Million
Investment From Biotechnology Value Fund, L.P.
Copiague,- February 3,
2000
American Biogenetic Sciences Diagnostic Test May Prove
to be Novel Marker for Life Threatening Complication
of Pregnancy
Copiague,- January
27, 2000
Abbott Laboratories and American Biogenetic Sciences
Sign Agreement to License Novel Neuroscience Compound
Copiague,- January 11,
2000
MABA is the New Symbol for American Biogenetic Sciences,
Inc. on OTC Bulletin Board
Copiague,- January 7,
2000
American Biogenetic Sciences, Inc. NASDAQ Smallcap
Market Listing Extension Denied
Copiague,- December 31,
1999
American Biogenetic Sciences, Inc. Seeks Extension
of NASDAQ Exception
Copiague,- December 3,
1999
American Biogenetic Sciences, Inc. Receives Extension
on Market Listing
Copiague,- July 21, 1999
American Biogenetic Sciences Signs Breakthrough Agreement
with the Chinese Academy of Medical Sciences to Market
and Sell Traditional Chinese Medicines Worldwide
Copiague,- July 14, 1999
American Biogenetic Sciences and Chinese Academy Join
Forces on Transgenic Quest
Copiague,- June 2, 1999
Study Finds American Biogenetic Sciences' TpP™
Test 97% Accurate in Excluding Deep Vein Thrombosis
Copiague,- May 10, 1999
American Biogenetic Sciences' TpP™ Test Identifies
Patients with Underlying Clotting Defects
Copiague,- May 6, 1999
Japanese Patent Granted on American Biogenetic Sciences'
Next-Generation Valproic Acid
Copiague,- April 6, 1999
American Biogenetic Sciences' Point of Care TpP Test
to Proceed to Clinical Evaluation
Copiague,- March 9,
1999
American Biogenetic Sciences, Inc Appoints former
Merck Senior Executive to Board of Directors.
Copiague,- February 24, 1999
American Biogenetic Sciences, Inc uses Chiral Technology
to Produce Single Isomer Version of Epilepsy Drug
ABS-103.
Copiague,- February 17, 1999
American Biogenetic Sciences, Inc in Full Compliance
with NASDAQ Requirements.
Copiague,- February 4, 1999
American Biogenetic Sciences, Inc Engages Investor
Relations Firm Redington, Inc.
Copiague,- February 3, 1999
American Biogenetic Sciences, Secures Japanese Notice
of Allowance for Patent Application.
Copiague,- January 25, 1999
American Biogenetic Sciences, Inc Signs Agreement
with FNG & Associates, Inc.
Copiague,- January 21, 1999
American Biogenetic Sciences, Inc Appoints Dr. Yale
Arkel Coordinator of Clinical Development.
Copiague,- January 6, 1999
M.H.Meyerson, Inc Announces Initiated Coverage of
ABS.
|
